⚠️ Ibogaine carries a real, documented risk of death — including in otherwise healthy individuals. Cardiac arrest is the leading cause of ibogaine-related fatalities and can occur without warning. Never take ibogaine outside a medically supervised setting with continuous cardiac monitoring.

Ibogaine Deaths: Causes, Statistics, and Prevention

Ibogaine is a powerful psychoactive alkaloid derived from the Tabernanthe iboga shrub native to Central Africa. It has demonstrated significant promise for treating opioid use disorder and other addictions, but it carries a narrow therapeutic window and a documented mortality risk that demands serious, evidence-based respect. This page compiles what is currently known about ibogaine-related deaths, who is most at risk, and what clinical safeguards meaningfully reduce that risk.

How Many People Have Died from Ibogaine?

Precise global mortality data is difficult to compile because ibogaine is unscheduled or unregulated in many countries, and deaths may be misattributed or unreported. However, several systematic analyses provide important benchmarks:

  • A 2012 review by Litjens & Brunt published in Clinical Toxicology identified 19 fatalities associated with ibogaine between 1990 and 2008, most involving pre-existing cardiac conditions or concurrent drug use.
  • A 2016 analysis by Meisner et al. in Clinical Toxicology catalogued at least 33 ibogaine-related deaths in the published literature through 2015, with cardiac arrhythmia identified as the dominant mechanism.
  • Researcher Kenneth Alper, who has tracked ibogaine cases globally since the 1990s, estimated approximately 1 death per 300 administrations in early uncontrolled settings — a rate that drops substantially under proper medical screening and monitoring.
  • A 2021 study in PLOS ONE (Ona et al.) noted that the majority of documented fatalities involved at least one identifiable risk factor that current screening protocols are designed to detect and exclude.

Importantly, no randomized controlled trials have been completed in large populations, so estimates carry uncertainty. The Global Ibogaine Therapy Alliance (GITA) and academic researchers continue to track outcomes, and real-world registries are expanding as legal treatment programs grow in Mexico, Canada, New Zealand, and Portugal.

Leading Causes of Ibogaine-Related Death

1. Cardiac Arrhythmia (QT Prolongation and Torsades de Pointes)

This is the single most documented cause of ibogaine fatality. Ibogaine and its primary metabolite noribogaine are potent hERG potassium channel blockers, which prolongs the cardiac QT interval — the electrical recovery phase of the heartbeat. When QT prolongation becomes severe (typically >500 ms), it can trigger Torsades de Pointes (TdP), a potentially fatal ventricular arrhythmia that can deteriorate into ventricular fibrillation and cardiac arrest (Koenig et al., 2014, Cardiovascular Toxicology).

QT prolongation from ibogaine is dose-dependent and can persist for 24–72 hours after administration, meaning the risk window extends well beyond the acute psychedelic experience. A 2020 study by Mash et al. in Frontiers in Pharmacology found mean QTc prolongation of approximately 100 ms in treated patients — a clinically significant elevation requiring continuous monitoring.

Risk is compounded dramatically by:

  • Pre-existing prolonged QTc interval (>450 ms in men, >470 ms in women)
  • Structural heart disease, cardiomyopathy, or a history of arrhythmia
  • Concurrent use of other QT-prolonging drugs (see Interactions section below)
  • Electrolyte abnormalities — particularly low potassium (hypokalemia) or low magnesium (hypomagnesemia), extremely common in people with active opioid or alcohol use disorder
  • Bradycardia (slow resting heart rate), which potentiates TdP risk

2. Respiratory Depression from Concurrent Opioid Use

Multiple documented fatalities have involved individuals who took opioids shortly before, during, or immediately after ibogaine administration — either by not disclosing use, using secretly during treatment, or returning to use before noribogaine fully cleared. Ibogaine modulates opioid receptor activity in complex ways, and the combination can produce unpredictable, severe respiratory depression (Alper et al., 2012).

This risk is particularly acute because ibogaine dramatically reduces opioid tolerance. A person who uses their typical pre-treatment opioid dose after ibogaine faces a life-threatening overdose risk equivalent to someone with little or no tolerance.

3. Aspiration and Vomiting

Nausea and vomiting are extremely common during ibogaine experiences — estimates range from 50–80% of patients (Schenberg et al., 2014). In a sedated or deeply altered state, aspiration of vomit can cause fatal aspiration pneumonia or acute asphyxiation. This is why continuous in-person monitoring by trained staff, proper body positioning, and nil-by-mouth protocols in the hours preceding administration are standard in responsible clinical settings.

4. Seizures

Ibogaine lowers the seizure threshold. Seizure-related deaths have been documented, particularly in individuals with undisclosed epilepsy or those undergoing severe benzodiazepine or alcohol withdrawal concurrently with ibogaine. Alcohol and benzodiazepine withdrawal itself carries seizure risk, and combining it with ibogaine is considered contraindicated by most clinical protocols.

5. Hepatotoxicity

Several case reports have identified acute liver failure as a contributing cause of death, particularly in individuals with pre-existing hepatic disease or who were taking hepatotoxic substances. Liver enzyme testing (AST, ALT, bilirubin) before treatment is a standard screening requirement at accredited clinics.

6. Trauma and Environmental Hazards

During the acute ibogaine experience, which typically lasts 18–36 hours, individuals are profoundly impaired in motor coordination and judgment. Unmonitored individuals have died from falls, drowning, and accidental injury. Continuous direct supervision is not optional — it is life-saving.

Absolute Contraindications: Who Should Never Take Ibogaine

The following conditions are considered absolute contraindications in virtually all responsible clinical protocols, including those from GITA and the Multidisciplinary Association for Psychedelic Studies (MAPS):

  • QTc interval >450 ms (men) or >470 ms (women) on a pre-treatment 12-lead ECG
  • Any diagnosed cardiac arrhythmia, including atrial fibrillation, ventricular tachycardia, or Wolff-Parkinson-White syndrome
  • Structural heart disease: cardiomyopathy, heart failure, congenital defects, significant valvular disease
  • History of sudden cardiac arrest or resuscitation
  • Long QT syndrome (congenital or acquired)
  • Liver failure or severe hepatic impairment
  • Active psychosis or a primary diagnosis of schizophrenia or schizoaffective disorder
  • Pregnancy
  • Current use of QT-prolonging medications without adequate washout (see below)
  • Active benzodiazepine or alcohol dependence without supervised detoxification first
  • Severe uncontrolled hypertension
  • Cerebellar ataxia (ibogaine may worsen coordination-related neurological conditions)

Critical Drug Interactions

The following drug classes and specific medications pose serious or potentially fatal interaction risks with ibogaine. This list is not exhaustive — any medication affecting cardiac conduction, liver metabolism (CYP2D6, CYP3A4), or CNS function requires evaluation by a physician before ibogaine treatment:

QT-Prolonging Medications (High Risk of Fatal Arrhythmia)

  • Methadone — itself a potent QT prolonger; the combination with ibogaine is associated with multiple documented deaths and is considered contraindicated; a medically supervised washout period of at least 10–14 days (sometimes longer) is required by most protocols
  • Antipsychotics: haloperidol, quetiapine, ziprasidone, risperidone, thioridazine
  • Antidepressants: tricyclics (amitriptyline, imipramine), citalopram, escitalopram at higher doses
  • Antibiotics: azithromycin, clarithromycin, fluoroquinolones (ciprofloxacin, levofloxacin)
  • Antifungals: fluconazole, ketoconazole
  • Antiemetics: ondansetron (Zofran), domperidone
  • Antiarrhythmics: amiodarone, sotalol, flecainide

Serotonergic Medications (Risk of Serotonin Syndrome)

  • SSRIs and SNRIs: fluoxetine, sertraline, paroxetine, venlafaxine — require a washout period (fluoxetine requires up to 5 weeks due to its long half-life); abrupt discontinuation also carries its own risks and must be managed by a physician
  • MAOIs: ibogaine has some MAOI properties; combining with other MAOIs or serotonergic drugs is dangerous
  • Tramadol: both serotonergic and opioid properties create compounded risk
  • St. John's Wort: herbal serotonergic; must be disclosed and discontinued

CYP2D6 Inhibitors (Impaired Ibogaine Metabolism)

Ibogaine is extensively metabolized by CYP2D6. Inhibitors of this enzyme — including fluoxetine, paroxetine, bupropion, and quinidine — can dramatically elevate ibogaine plasma levels, increasing both cardiac and neurological toxicity risk.

Central Nervous System Depressants

  • Opioids (including buprenorphine — typically requires 48–72 hour minimum washout; methadone requires longer)
  • Benzodiazepines — should not be used acutely before ibogaine; however, they are an essential rescue medication if seizures occur during treatment
  • Alcohol — both the intoxicating effects and withdrawal syndrome present compounding dangers
  • Gabapentinoids (gabapentin, pregabalin) — CNS depression risk; requires physician evaluation

What Responsible Clinics Do to Prevent Deaths

Legitimate ibogaine treatment centers — particularly those operating under medical oversight in jurisdictions such as Mexico, New Zealand, Portugal, and Canada — follow protocols that have demonstrably reduced mortality risk. These include:

Pre-Treatment Medical Screening

  • 12-lead ECG with QTc interval measurement — mandatory, usually repeated within days of treatment
  • Comprehensive metabolic panel: liver enzymes (AST, ALT, GGT, bilirubin), kidney function (BUN, creatinine), electrolytes (potassium, magnesium, sodium)
  • Complete blood count (CBC)
  • Full medication history and urine drug screen — including over-the-counter and herbal supplements
  • Cardiac history: personal and family history of arrhythmia, sudden cardiac death, syncope, palpitations
  • Echocardiogram for patients over 45 or with any cardiac history
  • Psychiatric evaluation to screen for contraindicated diagnoses

During Treatment Monitoring

  • Continuous cardiac telemetry (ECG monitoring) for the entire duration of the experience — a minimum of 24 hours, ideally 48–72 hours given noribogaine's prolonged activity
  • Pulse oximetry and regular vital signs
  • IV access established before dosing, with resuscitation equipment immediately available
  • Crash cart and defibrillator on-site
  • Trained medical staff — physician or experienced nurse — present throughout
  • 1:1 monitoring with trained sitter to prevent falls, manage vomiting, and observe neurological status
  • Electrolyte supplementation as indicated — correcting hypokalemia and hypomagnesemia before dosing is standard practice

Post-Treatment Monitoring

  • QTc re-measurement 24 and 48 hours post-dose
  • Supervised rest with restrictions on physical exertion (which can precipitate arrhythmia during the prolonged QT window)
  • Clear instructions not to use any substances — particularly opioids — during noribogaine clearance (typically 72+ hours)

The Danger of Unmonitored and Underground Administration

A substantial proportion of documented ibogaine fatalities have occurred in settings with no medical oversight: at home, in ceremony-style settings without clinical screening, or after purchasing ibogaine root bark or extracts online. The problems with these settings include:

  • No pre-treatment ECG — the most critical single screening tool
  • No electrolyte correction
  • No cardiac monitoring during the experience
  • No defibrillator or resuscitation capability
  • No trained personnel to recognize arrhythmia, seizure, or aspiration
  • Unknown purity and dosage of ibogaine product
  • Delayed emergency response due to reluctance to call 911 in unregulated settings

A 2018 case series in the Journal of Psychoactive Drugs (Brown & Alper) found that deaths were significantly more common in non-clinical settings. This is not an argument that clinical settings are without risk — they are not — but the data consistently show that proper screening and monitoring save lives.

Ibogaine vs. Noribogaine: The Extended Risk Window

A critical safety concept that even experienced users may not appreciate: ibogaine is rapidly metabolized to noribogaine, which has a half-life of approximately 28–49 hours — far longer than ibogaine itself (half-life approximately 7–8 hours). Noribogaine also prolongs the QT interval and maintains pharmacological activity, meaning:

  • The cardiac risk window extends well beyond the end of the psychedelic experience
  • Opioid use in the 72 hours after ibogaine carries compounded overdose and cardiac risk
  • Strenuous exercise, dehydration, and QT-prolonging drugs in the days following treatment remain genuinely dangerous
  • Medical personnel treating someone in the emergency department should be informed of ibogaine use, as standard cardiac or pain medications may be contraindicated

What to Do in an Emergency

If someone loses consciousness, has a seizure, stops breathing, or collapses during or after ibogaine treatment:

  1. Call emergency services immediately (911 in the US, 999 in the UK, 112 in the EU) — do not delay out of concern about legal consequences. Good Samaritan laws protect callers in many jurisdictions.
  2. Place the person in the recovery position if breathing but unconscious, to prevent aspiration
  3. Begin CPR if there is no pulse and no breathing — cardiac arrhythmia is survivable with prompt defibrillation
  4. Inform emergency responders of the substance taken, the time, and the approximate dose — this is essential for appropriate treatment (QT-prolonging emergency medications must be avoided)
  5. Do not administer opioids, stimulants, or other substances

Frequently Asked Questions

Precise mortality rates are difficult to establish due to incomplete global reporting. Researcher Kenneth Alper estimated approximately 1 death per 300 administrations in early uncontrolled settings. A 2016 review by Meisner et al. in Clinical Toxicology identified at least 33 deaths in the published literature through 2015. Rates appear substantially lower in accredited clinical settings with full cardiac screening and monitoring, though no large controlled trial has precisely quantified this difference. The conservative clinical position is that ibogaine carries a real, non-trivial mortality risk that only medical screening and monitoring can meaningfully reduce.
Yes, though risk is lower than in people with identifiable contraindications. Some documented deaths have occurred in individuals without a known prior cardiac history, because certain arrhythmia risks (such as a mildly prolonged QTc or silent structural abnormalities) are only detectable with a 12-lead ECG and cardiac workup. Additionally, aspiration, seizures, and trauma risks exist independently of cardiac status. This is why even apparently healthy individuals require full medical screening before ibogaine treatment, not just a self-assessment of fitness.
Methadone is itself one of the most potent QT-prolonging medications in clinical use — it blocks the same hERG potassium channels as ibogaine. Combining two strong hERG blockers dramatically amplifies QT prolongation and the risk of Torsades de Pointes arrhythmia. Multiple ibogaine fatalities have been linked to recent methadone use. Responsible clinical protocols require a supervised methadone taper and a minimum washout period — typically at least 10–14 days, with repeat ECG confirmation before proceeding — before ibogaine can be considered. Some protocols require transition to a shorter-acting opioid first. This transition itself requires medical management.
The available evidence consistently indicates yes — not because clinical settings are risk-free, but because they address the identifiable causes of ibogaine fatalities. Pre-treatment ECG screening excludes patients with dangerous baseline QTc intervals. Electrolyte correction reduces arrhythmia vulnerability. Continuous cardiac telemetry detects arrhythmia in time to intervene. On-site defibrillation can convert a potentially fatal rhythm. In-person monitoring prevents aspiration and injury. A 2018 case series in the Journal of Psychoactive Drugs found that non-clinical settings accounted for a disproportionate share of documented deaths. Home and ceremonial settings typically lack every one of these safeguards.
The acute psychedelic experience typically ends within 18–36 hours, but cardiac risk persists significantly longer due to the long half-life of noribogaine (approximately 28–49 hours). QTc elevation has been documented for 48–72 hours post-dose in clinical studies, including Mash et al. (2020) in Frontiers in Pharmacology. Responsible protocols require continuous cardiac monitoring for at least 24 hours and ideally 48–72 hours, with repeat ECG before discharge. Patients should avoid strenuous exertion, QT-prolonging medications, and substance use for several days after treatment. Any new symptoms — palpitations, dizziness, fainting — in this window warrant immediate emergency evaluation.
Emergency clinicians should be aware that ibogaine and noribogaine both prolong the QT interval for 48–72 hours after ingestion. Standard antiemetics like ondansetron (Zofran), many antipsychotics, and some antibiotics also prolong QT and should be avoided if possible. Activated charcoal may be considered for very recent oral ingestion if airway is protected. Cardiac monitoring (continuous telemetry) is essential. Magnesium sulfate IV is a first-line treatment for Torsades de Pointes. The American College of Medical Toxicology and Poison Control Centers (1-800-222-1222 in the US) can provide real-time guidance. Patients and companions should always disclose ibogaine use to EMS and ER staff — this information is medically essential, not incriminating.

Sources

  • Alper, K.R., Stajić, M., & Gill, J.R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412.
  • Meisner, J.A., Wilcox, S.R., & Richards, J.B. (2016). Ibogaine-associated cardiac arrest and death: Case report and review of the literature. Therapeutic Advances in Psychopharmacology, 6(2), 95–98.
  • Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: A delicate relation. Molecules, 20(2), 2208–2228.
  • Mash, D.C., et al. (2020). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 11, 61.
  • Litjens, R.P.W., & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302.
  • Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36.
  • Ona, G., et al. (2021). Ibogaine administration with noribogaine: Clinical, safety and pharmacological findings. PLOS ONE.
  • Schenberg, E.E., et al. (2014). Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology, 28(11), 993–1000.
  • Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. Currently available at gicare.org.
  • CredibleMeds / Arizona CERT QTDrugs List (currently maintained at crediblemeds.org) — comprehensive QT-prolonging drug database.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.